Linrodostat Explained
| Routes Of Administration: | Oral |
| Legal Status: | Investigational |
| Synonyms: | BMS-986205; ONO 7701 |
| Cas Number: | 1923833-60-6 |
| Unii: | 0A7729F42K |
| Chemspiderid: | 58828674 |
| Drugbank: | DB14986 |
| Iupac Name: | (2R)-N-(4-Chlorophenyl)-2-[(1s,4''S'')-4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide |
| C: | 24 |
| H: | 24 |
| Cl: | 1 |
| F: | 1 |
| N: | 2 |
| O: | 1 |
| Stdinchi: | 1S/C24H24ClFN2O/c1-15(24(29)28-20-9-6-18(25)7-10-20)16-2-4-17(5-3-16)21-12-13-27-23-11-8-19(26)14-22(21)23/h6-17H,2-5H2,1H3,(H,28,29)/t15-,16-,17+/m1/s1 |
| Stdinchikey: | KRTIYQIPSAGSBP-ZACQAIPSSA-N |
| Smiles: | FC1=CC=2C(=CC=NC2C=C1)[C@@H]3CC[C@]([C@H](C(NC4=CC=C(Cl)C=C4)=O)C)(CC3)[H] |
Linrodostat (development code BMS-986205) is an experimental drug being studied for its immunomodulating and antineoplastic activities.[1]
Linrodostat is an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1).[2] [3]
Linrodostat has entered clinical trials for a variety of cancer types including bladder cancer, head and neck cancer,endometrial cancer, gastric cancer, malignant melanoma, liver cancer, non-small cell lung cancer, and solid tumors.[4]
External links
- 10.1021/acs.oprd.9b00359 . Rapid Development of a Commercial Process for Linrodostat, an Indoleamine 2,3-Dioxygenase (IDO) Inhibitor . 2019 . Fraunhoffer KJ, Delmonte AJ, Beutner GL, Bultman MS, Camacho K, Cohen B, Dixon DD, Fan Y, Fanfair D, Freitag AJ, Glace AW, Gonzalez-Bobes F, Gujjar M, Haley MW, Hickey MR, Ho J, Iyer V, Maity P, Patel S, Rosso VW, Schmidt MA, Stevens JM, Tan Y, Wilbert C, Young IS, Yu M . 6 . Organic Process Research & Development . 23 . 11 . 2482–2498 . 208690975 .
Notes and References
- Web site: Linrodostat . . NCI Drug Dictionary .
- Balog A, Lin TA, Maley D, Gullo-Brown J, Kandoussi EH, Zeng J, Hunt JT . Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor . Molecular Cancer Therapeutics . 20 . 3 . 467–476 . March 2021 . 33298590 . 10.1158/1535-7163.MCT-20-0251 . 228087398 . free .
- News: IDO Inhibitor Development Shows Fresh Signs of Life Across Tumor Types . October 31, 2019 . onclive.com .
- Web site: Linrodostat . Adis Insight . Springer Nature Switzerland AG .
